Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has received an average rating of "Buy" from the eight analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $12.13.
FHTX has been the topic of a number of analyst reports. HC Wainwright raised Foghorn Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Citizens Jmp initiated coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 target price on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 target price on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. Finally, Citigroup initiated coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set an "outperform" rating on the stock.
Read Our Latest Research Report on Foghorn Therapeutics
Foghorn Therapeutics Trading Up 8.3%
Shares of FHTX traded up $0.34 during midday trading on Wednesday, reaching $4.46. 79,876 shares of the company were exchanged, compared to its average volume of 141,840. The stock has a 50-day moving average price of $4.00 and a 200-day moving average price of $4.73. The company has a market cap of $248.60 million, a price-to-earnings ratio of -2.32 and a beta of 3.04. Foghorn Therapeutics has a 1-year low of $2.94 and a 1-year high of $10.25.
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, hitting analysts' consensus estimates of ($0.30). The company had revenue of $5.95 million for the quarter, compared to analyst estimates of $4.96 million. Equities research analysts anticipate that Foghorn Therapeutics will post -1.55 earnings per share for the current year.
Institutional Trading of Foghorn Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C increased its holdings in Foghorn Therapeutics by 7.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,255,514 shares of the company's stock valued at $15,366,000 after buying an additional 227,628 shares during the last quarter. Raymond James Financial Inc. increased its holdings in Foghorn Therapeutics by 9.3% in the first quarter. Raymond James Financial Inc. now owns 2,218,352 shares of the company's stock valued at $8,097,000 after buying an additional 188,969 shares during the last quarter. Geode Capital Management LLC increased its holdings in Foghorn Therapeutics by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 682,863 shares of the company's stock valued at $3,224,000 after buying an additional 5,477 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Foghorn Therapeutics by 58.8% in the fourth quarter. Point72 Asset Management L.P. now owns 634,761 shares of the company's stock valued at $2,996,000 after buying an additional 235,059 shares during the last quarter. Finally, DAFNA Capital Management LLC increased its holdings in Foghorn Therapeutics by 63.2% in the first quarter. DAFNA Capital Management LLC now owns 304,752 shares of the company's stock valued at $1,112,000 after buying an additional 118,035 shares during the last quarter. 61.55% of the stock is owned by institutional investors.
About Foghorn Therapeutics
(
Get Free ReportFoghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Recommended Stories
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
